| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| MRK | Merck & Company, Inc. | $70.42 | $187.28B | N/A |
Why Merck (MRK) is a Top Dividend Stock for Your Portfolio
http://www.zacks.com/stock/news/845194/why-merck-mrk-is-a-top-dividend-stock-for-your-portfolio?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-845194
Mar 30, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
0
AstraZeneca's Imfinzi Gets FDA Nod for SCLC Label Expansion
http://www.zacks.com/stock/news/845152/astrazenecas-imfinzi-gets-fda-nod-for-sclc-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-845152
Mar 30, 2020 - AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected.
0
Here's Why You Should Buy Lilly Stock Amid Coronavirus Crisis
http://www.zacks.com/stock/news/851267/heres-why-you-should-buy-lilly-stock-amid-coronavirus-crisis?cid=CS-ZC-FT-analyst_blog|rank_focused-851267
Apr 02, 2020 - Lilly (LLY) enjoys strong fundamentals, which can help it withstand the short-term impact of the pandemic.
0
Why Merck (MRK) is Poised to Beat Earnings Estimates Again
http://www.zacks.com/stock/news/853066/why-merck-mrk-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-853066
Apr 03, 2020 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
0
Pharma Stock Roundup: JNJ & SNY's Coronavirus Product Development, Other Updates
http://www.zacks.com/stock/news/853058/pharma-stock-roundup-jnj-snys-coronavirus-product-development-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-853058
Apr 03, 2020 - J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
0
Pages: 1
Page 1